Treatment News : Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 15, 2012

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

People living with both HIV and the hepatitis C virus (HCV) experience high hepatitis cure rates from an Incivek (telaprevir)–based triple combination therapy, compared with those taking interferon and ribavirin alone, aidsmap reports. Vertex Pharmaceuticals presented the results of its Phase II trial at the annual meeting of the American Association for the Study of Liver Diseases (AALSD) in Boston. The findings echoed and re-affirmed previous results announced at the 2012 Conference on Retroviruses and Opportunistic Infections in March.

The randomized controlled trial examined the effects of Incivek along with pegylated interferon and ribavirin among HCV treatment-naive coinfected people with HCV genotype-1, the most common strain and the most difficult to treat. Divided into two arms, the study examined 13 participants with CD4 counts above 500 who had not yet taken antiretrovirals (ARVs) for HIV, as well as 47 patients on ARVs with a stable viral load. All participants randomly received either Incivek or a placebo along with pegylated interferon and ribavirin for 12 weeks, followed by another 36 weeks of just the peg-interferon plus ribavirin combination.

Across the board, 74 percent of those taking Incivek triple combination therapy maintained a sustained virological response (SVR, considered a cure) 24 weeks after finishing treatment, while only 45 percent of the control group achieved the same. Those not taking antiretrovirals experienced respective SVR rates of 71 and 33 percent. Side effects were elevated among those taking Incivek, with the most notable increased including itching, headache, nausea, skin rash and dizziness. However, the overall safety and tolerability profile of the triple combination therapy proved comparable to previous studies of people living with only hepatitis C.

To read the aidsmap article, click here.

Search: Hepatitis C, HCV, virus, HIV, cure, Incivek, telaprevir, triple combination therapy, Vertex Pharmaceuticals, American Association for the Study of Liver Diseases, AASLD, Conference on Retroviruses and Opportunistic Infections, CROI, pegylated interferon, ribavirin, treatment-naive, sustained virologic response, SVR, safety, tolerability


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chrisf
    san jose
    California


    Poz_Qt
    Columbus
    Ohio


    Sexynyrican
    Brooklyn
    New York


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.